Orbital Schwannoma

Key Points at a Glance

Key Points of This Disease

• Orbital schwannoma is a benign tumor arising from Schwann cells of peripheral nerves, accounting for approximately 1-2% of all orbital tumors, making it a rare disease.
• It commonly occurs in individuals aged 20-50 years with no gender predilection. Early symptoms are often absent, and slowly progressive proptosis is the main complaint.
• The first branch of the trigeminal nerve is the most common origin, and it can occur anywhere within the orbit.
• A definitive diagnosis cannot be made by clinical examination alone; histopathological diagnosis is essential.
• MRI is the most useful imaging modality, and dynamic MRI helps differentiate from cavernous hemangioma.
• Standard treatment is complete surgical resection with preservation of the capsule, and the approach is selected based on tumor location.
• Malignant transformation is rare, but residual tumor increases the risk of recurrence.

1. What is orbital schwannoma?

Orbital schwannoma is a type of peripheral nerve sheath tumor, a benign tumor arising from Schwann cells that form the myelin sheath of peripheral nerves.

The incidence within the orbit is approximately 1–2% of all orbital tumors in Japan. International reports vary slightly, ranging from 1–6%¹⁾ or 1–6.5%²⁾. In a Japanese series of 735 benign orbital tumors, schwannoma accounted for 38 cases (about 5%), ranking sixth.

The peak age is 20 years and older, most common in the 20s to 50s²⁾, with no gender predilection. Pediatric cases are rare. It often originates from the ciliary nerves of the trigeminal nerve, but can arise from any nerve within the orbit, such as the supraorbital nerve, infraorbital nerve, and trochlear nerve. Malignant transformation is rare.

An association with neurofibromatosis has been reported; approximately half of orbital schwannomas are associated with neurofibromatosis. Orbital involvement in neurofibromatosis occurs in 11–28% of cases, and the risk of developing schwannoma is 1.5%.

Q How rare is orbital schwannoma?

A

In Japan, it accounts for about 1–2% of all orbital tumors and about 5% of benign orbital tumors, ranking sixth in frequency. International reports also classify it as rare, at 1–6.5%²⁾. It is mostly seen in adults, and pediatric cases are even rarer.

2. Main symptoms and clinical findings

Subjective symptoms

In the early stage, subjective symptoms are often absent, and it is not uncommon to be discovered incidentally on imaging.

• Proptosis: The most common complaint. It progresses very slowly over several years. Often without edema, redness, or pain.
• Diplopia and restricted eye movement: Seen in advanced cases.
• Visual loss: Occurs when the optic nerve is compressed. May be accompanied by scotoma, color vision abnormalities, and decreased contrast sensitivity.
• Pain and sensory abnormalities: May occur in the distribution area of the affected nerve.
• Sudden symptom changes: If necrosis or hemorrhage occurs inside the tumor, sudden inflammatory symptoms may appear.

As an example, a 55-year-old woman with a 20 mm × 15 mm mass in the right superior orbit that enlarged over 4 years has been reported, maintaining visual acuity of 20/20 ¹⁾. There is also a case of rapid enlargement from 1 cm to 5 cm during pregnancy, with abducens nerve palsy and mydriasis ³⁾.

Clinical Findings

• Non-pulsatile proptosis: When arising from the intraconal space, the eye protrudes straight forward; when extraconal, it deviates to the opposite side.
• Downward displacement of the eye: Most tumors infiltrate the superior orbital quadrant, causing downward displacement of the eye.
• Palpable mass: In severe cases, an orbital mass may be palpable.
• Ocular motility and visual function impairment are uncommon: Because some nerve fibers of the affected nerve bundle remain non-tumorous, impairment is surprisingly minimal.
• Presence of a capsule: The tumor has a capsule and shows little infiltration or adhesion to surrounding tissues.
• Bilateral occurrence is extremely rare: Only one case has been reported so far.

Q Do symptoms of orbital schwannoma appear suddenly?

A

Typically, it progresses very slowly over several years and is often asymptomatic in the early stages. However, if necrosis or hemorrhage occurs inside the tumor, symptoms may change suddenly. There are also reports of rapid enlargement during pregnancy due to hormonal influences or increased blood flow ³⁾.

3. Causes and Risk Factors

Orbital schwannoma involves neoplastic proliferation of Schwann cells that form the myelin sheath of peripheral nerves. Schwann cells are derived from the neural crest.

• Nerve of origin: Most commonly from the first branch of the trigeminal nerve. Rarely, it can arise from the second branch, oculomotor nerve, trochlear nerve, or abducens nerve.
• Association with neurofibromatosis:
  • Neurofibromatosis type 1: Biallelic loss of the neurofibromin gene at 17q11.2 leads to uncontrolled Ras signaling, promoting Schwann cell proliferation.
  • Neurofibromatosis type 2: Deletion of the merlin gene at 22q11.2 promotes Schwann cell proliferation.
• Pregnancy: Hormonal influences and increased blood flow may cause rapid growth during pregnancy³⁾.
• Rarity of location: Occurrence within extraocular muscles is extremely rare, with only 6 cases reported in the literature²⁾.

Expert Supplement

Orbital schwannomas associated with neurofibromatosis may coexist with neurofibromas and can be multiple, unlike sporadic cases. If systemic neurofibromatosis is diagnosed and there is no compression of the optic nerve or ocular motor nerves, observation may be chosen.

4. Diagnosis and Examination Methods

Definitive diagnosis based solely on clinical examination is nearly impossible; histopathological diagnosis is essential.

Comparison of Imaging Findings

The main imaging characteristics are shown below.

Examination	Solid Lesion	Cystic Lesion
CT	Homogeneous enhancement	Heterogeneous content, partial enhancement
MRI T1	Low signal, homogeneous	Low signal
MRI T2	High signal, homogeneous	Mixed high and low signal in cystic areas

• CT scan: Appears as a well-defined oval or fusiform mass. It expands without eroding bone (thinning of bone) and is usually located outside the muscle cone.
• MRI: Most useful for diagnosis. Shows low signal on T1-weighted images and high signal on T2-weighted images. Cystic degeneration is seen in about 41% of cases. Antoni A type shows intermediate signal on T1 and T2, while Antoni B type shows low signal on T1 and high signal on T2. If the mass fills the orbital apex, it is often a schwannoma.
• Dynamic MRI: Useful for differentiation from cavernous hemangioma. Cavernous hemangioma shows a delayed enhancement pattern, whereas schwannoma shows a plateau washout pattern. Dynamic MRI is particularly effective when the lesion is spherical and within the muscle cone, making differentiation difficult.
• Ultrasound (B-mode): Appears as a round, well-defined solid lesion. Acoustic voids suggest intratumoral hemorrhage.

Histopathological Features

• Antoni A type: High cellular density, with palisading of spindle cells and formation of Verocay bodies (acellular areas surrounded by palisading nuclei).
• Antoni type B: low cellularity, with vacuolated cells, foamy histiocytes, and hyalinized blood vessels in a myxoid matrix.
• Both types often coexist. In cases with cystic degeneration, Antoni type B or cystic degeneration predominates ²⁾.
• Immunohistochemistry: S-100 protein is strongly positive. SOX10, p16, and neurofibromin are positive; epidermal growth factor receptor (EGFR) is negative.
• Histologic subtypes: conventional, cellular, plexiform, melanotic, and ancient type.

Differential Diagnosis

Differential diagnoses include neurofibroma, malignant peripheral nerve sheath tumor, meningioma, cavernous hemangioma, lymphangioma, dermoid cyst, lymphoma, and solitary fibrous tumor. Distinguishing localized neurofibroma from schwannoma is not possible preoperatively and requires immunohistochemical staining such as S-100 protein.

Q Can a definitive diagnosis be made by imaging alone?

A

A definitive diagnosis based solely on clinical examination is almost impossible; histopathological diagnosis is required. MRI and dynamic MRI are useful for differentiating from other orbital tumors, but the final diagnosis is confirmed by pathological examination of the surgically removed tissue.

5. Standard Treatment

Surgery (First Choice)

The main treatment is excision, ideally performed while maintaining the integrity of the capsule. Strong traction can damage the fragile tissue within the tumor, making complete removal difficult. Residual tumor increases the risk of recurrence.

The surgical approach is selected based on the tumor location.

Anterior Approach

Superior lesions: Anterior orbitotomy (upper eyelid crease incision or subbrow incision)

Inferior and medial lesions: Transconjunctival incision

Medial anterior lesions: Transcaruncular incision

Lateral and skull base approach

Superolateral lesions: Lateral orbitotomy

Orbital apex and tip: Craniotomy with skull base approach. Because working space is difficult to secure and the risk of visual impairment is high, lateral orbitotomy may be recommended.

Cases involving the superior orbital fissure: Combined surgery with a neurosurgeon is recommended.

• Endoscopic endonasal approach: Indicated for lesions of the medial posterior wall (orbital apex).
• Clock-face access algorithm (Paluzzi classification): The endonasal approach corresponds to 1–7 o’clock, the lateral approach to 8–10 o’clock, and the transcranial approach to 9–1 o’clock ³⁾.

If the patient already has a diagnosis of systemic neurofibromatosis, observation may be chosen if there is no visual loss or diplopia due to compression of the optic nerve or oculomotor nerves. Orbital lesions in neurofibromatosis are difficult to completely resect and often recur.

Treatment considerations

Strong traction on the tumor may damage fragile internal tissues such as necrotic areas or cysts, making complete resection difficult. If part of the tumor remains, the risk of recurrence increases, so careful resection preserving the capsule is important.

Radiation therapy

Considered when surgery is difficult or for residual lesions after surgery.

• Gamma knife stereotactic radiosurgery: Reports indicate tumor stabilization or shrinkage in 6 of 7 cases. However, visual loss occurred in 2 cases.
• Optic neuropathy has been observed even with low doses of 8–12 Gy, and single-fraction irradiation for lesions at the orbital apex is not recommended (fractionated irradiation is indicated).
• Indications: Small, unresectable, inaccessible, or postoperative residual benign schwannoma.

Orbital Decompression Surgery

For unresectable cases, bony or fatty orbital decompression may be chosen to improve quality of life (QOL). Indications include benign, slow-growing lesions with preserved vision, no rapid deterioration, and no malignant features. Side effects may include diplopia, hypoglobus, enophthalmos, and rarely cerebrospinal fluid leakage.

Q Are there non-surgical treatment options?

A

Gamma knife radiotherapy (stabilization or shrinkage in 6 of 7 cases) and orbital decompression (for QOL improvement) are options. However, radiotherapy carries a risk of optic neuropathy, and single-fraction irradiation to the orbital apex is not recommended. Indications depend on tumor size, location, and symptoms.

6. Pathophysiology and Detailed Pathogenesis

Schwann cells are derived from the neural crest and form the myelin sheath of peripheral nerves. Tumors grow eccentrically from the parent nerve and, unlike neurofibromas, do not diffusely infiltrate.

The molecular mechanisms associated with neurofibromatosis are as follows.

• Neurofibromatosis type 1: Biallelic loss of the neurofibromin gene at 17q11.2 → uncontrolled Ras signaling → enhanced Schwann cell proliferation.
• Neurofibromatosis type 2: Deletion of the merlin gene at 22q11.2 → enhanced Schwann cell proliferation.

The biphasic histological pattern (Antoni A + Antoni B) has the following pathological features.

Antoni A Pattern

Cell density: High

Arrangement: Spindle cells arranged in parallel, forming palisading structures.

Verocay bodies: Nuclear-free zones surrounded by palisading nuclear clusters.

Staining: Periodic acid–Schiff (PAS) and laminin positive (each cell forms a basement membrane).

Antoni B type

Cell density: Low

Arrangement: Vacuolated cells arranged in sheets within a myxoid matrix.

Stroma: Foamy histiocytes and hyalinized blood vessels are present.

MRI correlation: Corresponds to T2 hyperintense areas and coincides with cystic degeneration sites.

Immunohistochemistry shows strong positivity for S-100 protein, and positivity for SOX10, p16, and neurofibromin, with negativity for epidermal growth factor receptor. Type IV collagen staining can identify pericellular collagen deposition.

Subtype-specific features: In the cellular type, Antoni B pattern is minimal or absent and Verocay bodies are insufficient; differentiation from smooth muscle tumors requires smooth muscle actin staining. The plexiform type is predominantly Antoni A pattern without mitosis, atypia, or necrosis, and is S-100 positive, distinguishing it from sarcoma. The melanotic type shows positivity for HMB-45 and Melan-A, making differentiation from malignant melanoma difficult. The degenerative (ancient) type shows microcysts, hemorrhage, calcification, atypia, and pleomorphism due to degeneration, but is distinguished from sarcoma by the absence of mitotic figures and S-100 positivity.

Regarding rapid enlargement during pregnancy, hormonal influences and increased blood flow have been suggested as possible causes ³⁾, but the detailed mechanism awaits future elucidation.

---

7. Latest Research and Future Perspectives (Research-stage Reports)

For patients: Please read carefully

The following content is currently at the research stage or under clinical trial and is not standard treatment available at general hospitals. It is reference information for professionals regarding future medical developments.

Endoscopic Endonasal Combined with Transorbital Approach (EETOA)

This is a new minimally invasive technique that enables total resection of schwannomas extending from the cavernous sinus to the orbit while avoiding craniotomy.

Tanji et al. (2025) performed an endoscopic endonasal combined with transorbital approach postpartum in a 27-year-old woman with an orbital schwannoma originating from the first branch of the trigeminal nerve that rapidly enlarged from 1 cm to 5 cm during pregnancy, causing abducens nerve palsy and mydriasis ³⁾. Intraoperative MRI confirmed total resection, with an operative time of 5.5 hours and discharge on postoperative day 4. Postoperatively, abducens nerve palsy improved but mydriasis persisted.

Advantages of multi-port surgery include short access distance to the target, avoidance of crossing nerves and blood vessels, and securing a multi-directional field of view³⁾.

Comparison of surgical approaches

The characteristics of the three main approaches are shown below.

Approach	Main indication site	Features
Transcranial (craniotomy)	Orbital apex, cavernous sinus	Wide surgical field, highly invasive
Endoscopic endonasal	Medial, orbital apex	Minimally invasive, limited field of view
Endoscopic endonasal + transorbital combined (EETOA)	Cavernous sinus to orbital extension	Avoids craniotomy, total resection possible

Cases of rapid tumor enlargement during pregnancy continue to accumulate, and elucidating the mechanisms of enlargement mediated by hormones and increased blood flow remains a future challenge ³⁾.

---

8. References

1. Uppal S, Saggar V, Scalia G, Umana GE, Sharma M, Chaurasia B.. Unilateral orbital schwannoma arising from the supraorbital nerve: Report of a rare case. Clin Case Rep. 2024;12(1):e8381. doi:10.1002/ccr3.8381. PMID:38161625; PMCID:PMC10753633.
2. Afshar P, Rafizadeh SM, Eshraghi N, Mansourian S, Aghajani A, Asadi Amoli F.. Orbital schwannoma arising within inferior rectus muscle: A rare orbital tumor. Am J Ophthalmol Case Rep. 2024;36:102172. doi:10.1016/j.ajoc.2024.102172. PMID:39314251; PMCID:PMC11417565.
3. Tanji M, Sano N, Hashimoto J, Kikuchi M, Matsunaga M, Kitada Y, Yamamoba M, Takeuchi Y, Makino Y, Hattori EY, Terada Y, Mineharu Y, Arakawa Y.. Multiport combined endoscopic endonasal and transorbital approach to orbital schwannoma. Surg Neurol Int. 2025;16:98. doi:10.25259/sni_246_2024. PMID:40206748; PMCID:PMC11980739.